Novaquin
meloxicam
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Novaquin. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Novaquin.
For practical information about using Novaquin, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Novaquin
|
Agency product number |
EMEA/V/C/003866
|
Active substance |
meloxicam
|
International non-proprietary name (INN) or common name |
meloxicam
|
Species |
Horses
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QM01AC06
|
Publication details | |
---|---|
Marketing-authorisation holder |
Le Vet Beheer B.V.
|
Revision |
4
|
Date of issue of marketing authorisation valid throughout the European Union |
08/09/2015
|
Contact address |
Le Vet Beheer B.V.
Wilgenweg 7 3421 TV Oudewater The Netherlands |
Product information
27/01/2022 Novaquin - EMEA/V/C/003866 - IG1436
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.